SCHEMBL20008773

SCHEMBL20008773

C/C=C\C(=N)c1cc(N)ccc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 4/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 6/20 0.42
CYP3A4 P08684 3/20 0.38
PDE10A Q9Y233 1/20 0.38
KDM4E B2RXH2 3/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
RECQL P46063 3/20 0.33
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
KMT2A Q03164 4/20 0.32
MAPK1 P28482 1/20 0.32
PLA2G7 Q13093 1/20 0.32
MEN1 O00255 3/20 0.32
THRB P10828 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
ALOX15 P16050 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22889918 0.84 THRB (0.44) CASP1TSHRALDH1A1CYP3A4PDE10A
SCHEMBL25732408 0.81 CYP2D6 (0.40) TSHRALDH1A1CYP3A4KDM4ELMNA
SCHEMBL22889739 0.81 CASP1 (0.39) CASP1TSHRALDH1A1CYP3A4PDE10A
SCHEMBL19061357 0.77 CASP1 (0.41) CASP1TSHRALDH1A1CYP3A4PDE10A
SCHEMBL26084626 0.72 CASP1 (0.37) CASP1TSHRALDH1A1CYP3A4PDE10A
SCHEMBL20008147 0.70 CASP1 (0.35) CASP1TSHRALDH1A1CYP3A4PDE10A
SCHEMBL13004199 0.69 CASP1 (0.48) CASP1TSHRALDH1A1CYP3A4PDE10A
SCHEMBL25732476 0.69 CYP2D6 (0.41) TSHRALDH1A1CYP3A4KDM4EMAPT
SCHEMBL25732483 0.69 PRSS1 (0.48) TSHRALDH1A1PRSS1PRSS2PRSS3
SCHEMBL14964429 0.69 ALDH1A1 (0.52) CASP1TSHRALDH1A1CYP3A4PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 EP disclosed